Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice

Por Ravaud, A, Bedane, C, Geoffrois, L, Lesimple, T, Delaunay, M
Publicado em 1999

EPOCK study protocol: a mixed-methods research program evaluating cancer care coordination nursing occupations in France as a complex intervention

Por Colombani, F., Sibé, M., Kret, M., Quintard, B., Ravaud, A., Saillour-Glénisson, F.
Publicado no BMC Health Serv Res (2019)

Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension.

Por Calès, P, Grasset, D, Ravaud, A, Meskens, C, Blanc, M, Vinel, J P, Cotonat, J, Pascal, J P
Publicado em 1989

Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding.

Por Calès, P, Desmorat, H, Vinel, J P, Caucanas, J P, Ravaud, A, Gerin, P, Brouet, P, Pascal, J P
Publicado em 1990

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

Por Ravaud, A., Négrier, S., Cany, L., Merrouche, Y., Le Guillou, M., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T.
Publicado em 1994

A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.

Por Ravaud, A., Legrand, E., Delaunay, M. M., Bussières, E., Coulon, V., Cany, L., Huet, S., Verdier, D., Kind, M., Chomy, F.
Publicado em 1995

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial

Por Ravaud, A, Delaunay, M, Chevreau, C, Coulon, V, Debled, M, Bret-Dibat, C, Courbon, F, Gualde, N, Bui, B Nguyen
Publicado em 2001

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II t...

Por Ravaud, A, Trufflandier, N, Ferrière, J M, Debled, M, Palussière, J, Cany, L, Gaston, R, Mathoulin-Pélissier, S, Bui, B N
Publicado em 2003

Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials.

Por Ravaud, A., Bui, N. B., Coindre, J. M., Lagarde, P., Tramond, P., Bonichon, F., Stöckle, E., Kantor, G., Trojani, M., Chauvergne, J.
Publicado em 1992

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

Por Rugo, H. S., Hortobagyi, G. N., Yao, J., Pavel, M., Ravaud, A., Franz, D., Ringeisen, F., Gallo, J., Rouyrre, N., Anak, O., Motzer, R.
Publicado no Ann Oncol (2016)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

Por Bracarda, S, Hutson, T E, Porta, C, Figlin, R A, Calvo, E, Grünwald, V, Ravaud, A, Motzer, R, Kim, D, Anak, O, Panneerselvam, A, Escudier, B
Publicado em 2012

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

Por Staehler, M, Motzer, R J, George, D J, Pandha, H S, Donskov, F, Escudier, B, Pantuck, A J, Patel, A, DeAnnuntis, L, Bhattacharyya, H, Ramaswamy, K, Zanotti, G, Lin, X, Lechuga, M, Serfass, L, Paty, J, Ravaud, A
Publicado no Ann Oncol (2018)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Por Motzer, R.J., Tannir, N.M., McDermott, D.F., Frontera, O. Arén, Melichar, B., Choueiri, T.K., Plimack, E.R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C.K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C.H., Tomita, Y., Castellano, D., Rini, B.I., Chen, A.C., Mekan, S., McHenry, M.B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H.J., Escudier, B.
Publicado no N Engl J Med (2018)